NL005 Animal Experiments and Phase II Clinical Study Paper

https://academic.oup.com/cardiovascres/advance-article/doi/10.1093/cvr/cvaf223/8322149

Cardiovascular Research (2025) 00, 1–12 https://doi.org/10.1093/cvr/cvaf223

Article on the Phase III Clinical Trial of Donaperminogene Seltoplasmid Ingection for the Treatment of Rutherford Class 5 Severe Lower Limb Ischemia (HOPE CLTI-2)

Seltoplasmid promotes ulcer healing versus placebo for treating patients with chronic limb-threatening ischemia: HOPE CLTI-2 trial

Molecular Therapy. April 11, 2025: S1525-0016(25)00283-7.

Study on the Mechanism of Action and Injection Site Selection for Recombinant Human Hepatocyte Growth Factor Naked Plasmid in the Treatment of Chronic Ischemic Diseases

Optimal injection sites for therapeutic angiogenesis: HGF-mediated regulation of HIF-1α via MAPK/PI3K pathways in hypoxic endothelial cells

Tissue and Cell (2025), doi: https://doi.org/10.1016/j.tice.2025.102871.

Systematic Review and Meta-Analysis of Recombinant Human Hepatocyte Growth Factor Naked Plasmid for the Treatment of Chronic Ischemic Diseases

Recombinant Human Hepatocyte Growth Factor Plasmids for Treating Patients with Chronic Limb Threatening Ischaemia: A Systematic Review and Meta- analysis

European Journal of Vascular & Endovascular Surgery   (2024)

https://doi.org/10.1016/j.ejvs.2024.07.016.

NL003 Phase II Clinical Trial Long-term Follow-up Results Paper

Nine-year follow-up of patients receiving recombinant human hepatocyte growth factor nude plasmid DNA for critical limb ischemia: Updated safety and efficacy results

Vascular Investigation and Therapy (ISSN: 2589-9686) DOI: 10.4103/vit_21_24

NL003 Phase III Clinical Trial Protocol Paper

Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials

American Heart Journal, vol. 2022 Aug 21;254:88-101.

NL003 Phase II Clinical Trial Paper

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia

Molecular Therapy. 2019 Dec 4;27(12):2158-2165.

NL003 Phase I Clinical Trial Paper

A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.

The Journal of Gene Medicine. 2011 Nov;13(11):602-10.

NL005 Phase I Clinical Trial Paper

A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

  Journal of Cellular and Molecular Medicine. August 4, 2021. doi: 10.1111/jcmm.16693.